FDA Greenlights Eli Lilly's Oral Weight-Loss Medication Foundayo
The U.S. Food and Drug Administration (FDA) granted approval on Wednesday for Foundayo, a new oral weight-loss drug developed by Eli Lilly, based in Indianapolis. This once-daily tablet, also known as orforglipron, represents a significant advancement in the GLP-1 drug category, which mimics natural hormones to regulate appetite and promote feelings of fullness.
Expanding Access to GLP-1 Treatments
David A. Ricks, chair and CEO of Eli Lilly, highlighted in a statement that fewer than 10% of individuals who could benefit from GLP-1 drugs currently use them, often due to barriers such as access issues, stigma, or perceived complexity. "We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications," Ricks emphasized. The approval aims to make weight-loss treatment more accessible, particularly for those who have avoided injectable options because of cost, needle discomfort, or strict dosing requirements.
Key Features and Pricing Details
Foundayo offers several advantages over existing treatments. Unlike the Wegovy pill, which must be taken on an empty stomach first thing in the morning, Foundayo can be consumed at any time of day without regard to meals, potentially improving patient adherence. Patients typically start with the smallest dose and gradually increase it to minimize side-effects.
In terms of cost, the starting dose is projected to be approximately $149 per month for those paying out-of-pocket, similar to Wegovy. Higher strengths may reach up to $349 monthly. Insurance coverage remains uncertain for many private plans, but under a proposal from the Trump administration, Medicare could begin covering certain patients as early as this summer, with copayments potentially as low as $50 per month.
Market Impact and Availability
This approval intensifies competition in the rapidly growing GLP-1 drug market, with Foundayo entering just three months after Novo Nordisk's Wegovy pill. Eli Lilly submitted the drug under a fast-track program for medications of national importance, expediting its review process. According to CNBC, the pill will begin shipping on Monday through LillyDirect, a direct-to-consumer service, and is expected to be available in pharmacies and telehealth services shortly thereafter.
The introduction of Foundayo could significantly broaden treatment options for millions of Americans struggling with obesity, offering a more convenient oral alternative that may enhance consistency and overall health outcomes.
